Aardvark Therapeutics Corp - AARD Quarterly EPS earnings growth

Aardvark Pharma - graphic logo of issuer AARD

Aardvark Therapeutics Inc (AARD) is building a defensive moat through its innovative small-molecule platform. Quarterly EPS variation confirms the successful development of proprietary formulas for long-term metabolic treatment. Strong pricing power is driven by the uniqueness of ARD-101, which suppresses appetite without the use of hormones. The value of -16.70 captures the current state of the parameter, reflecting earnings per share dynamics amid macroeconomic shifts.

Aardvark Therapeutics (AARD) - Year-over-year earnings per share growth for the last twelve months from 02/14/2025 to 11/18/2026

Financial and market metric breakdowns for Aardvark Therapeutics Inc (AARD)

- share price and consensus valuation forecast:
Analysis of all company metrics:Aardvark Therapeutics Inc
Manufactured product of Aardvark Pharma

To assess the fundamental quality of Aardvark Therapeutics Inc (AARD), investors must analyze the dynamics of net earnings per share. This indicator measures quarterly changes in yield, reflecting the business's sensitivity to the cost of capital and global liquidity. By analyzing the quarterly earnings per share growth chart, one can identify the risks of price drawdowns during cash flow contractions. The biopharmaceutical company's patent portfolio and liquid reserves minimize these threats. Such a capital structure ensures the long-term sustainability of its developments.

Competitors of Aardvark Therapeutics Inc (AARD)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS